 Kyle Rove
Concepts (286)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urologic Surgical Procedures | 11 | 2024 | 107 | 3.640 |
Why?
| | Prostatic Neoplasms | 17 | 2014 | 1016 | 3.000 |
Why?
| | Androgen Antagonists | 5 | 2014 | 79 | 1.960 |
Why?
| | Perioperative Care | 3 | 2024 | 151 | 1.880 |
Why?
| | Urology | 5 | 2024 | 57 | 1.790 |
Why?
| | Analgesics, Opioid | 8 | 2024 | 898 | 1.770 |
Why?
| | Pain, Postoperative | 5 | 2024 | 228 | 1.760 |
Why?
| | Urinary Bladder, Neurogenic | 3 | 2024 | 35 | 1.560 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2024 | 336 | 1.370 |
Why?
| | Urinary Bladder | 4 | 2022 | 175 | 1.280 |
Why?
| | Postoperative Complications | 9 | 2024 | 2476 | 1.280 |
Why?
| | Urodynamics | 3 | 2024 | 35 | 1.140 |
Why?
| | Testosterone | 5 | 2015 | 371 | 1.110 |
Why?
| | Urinary Bladder Neoplasms | 3 | 2017 | 227 | 0.940 |
Why?
| | Abdominal Neoplasms | 1 | 2024 | 34 | 0.930 |
Why?
| | Testicular Neoplasms | 2 | 2016 | 104 | 0.920 |
Why?
| | Practice Patterns, Physicians' | 3 | 2024 | 1264 | 0.900 |
Why?
| | Specialties, Surgical | 1 | 2025 | 73 | 0.880 |
Why?
| | Physicians, Women | 1 | 2025 | 70 | 0.880 |
Why?
| | Neoplasms, Hormone-Dependent | 2 | 2014 | 38 | 0.860 |
Why?
| | Surgeons | 2 | 2025 | 259 | 0.850 |
Why?
| | Propensity Score | 1 | 2024 | 265 | 0.810 |
Why?
| | Child | 27 | 2024 | 20853 | 0.810 |
Why?
| | Delphi Technique | 1 | 2024 | 222 | 0.810 |
Why?
| | Urinary Bladder Diseases | 1 | 2022 | 18 | 0.810 |
Why?
| | Drug Prescriptions | 1 | 2024 | 246 | 0.800 |
Why?
| | Pediatrics | 3 | 2024 | 1052 | 0.790 |
Why?
| | Ureter | 1 | 2022 | 35 | 0.780 |
Why?
| | Gonadotropin-Releasing Hormone | 3 | 2014 | 207 | 0.760 |
Why?
| | Consensus | 2 | 2024 | 612 | 0.760 |
Why?
| | Postoperative Nausea and Vomiting | 1 | 2020 | 11 | 0.710 |
Why?
| | Urologic Diseases | 2 | 2018 | 38 | 0.710 |
Why?
| | Length of Stay | 8 | 2024 | 1121 | 0.700 |
Why?
| | Spinal Dysraphism | 2 | 2022 | 67 | 0.690 |
Why?
| | Analgesia | 1 | 2020 | 93 | 0.660 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2024 | 566 | 0.610 |
Why?
| | Humans | 58 | 2025 | 129212 | 0.600 |
Why?
| | Wolfram Syndrome | 1 | 2018 | 4 | 0.600 |
Why?
| | Pons | 1 | 2018 | 30 | 0.590 |
Why?
| | Bone Neoplasms | 2 | 2011 | 231 | 0.590 |
Why?
| | Urination | 1 | 2018 | 44 | 0.580 |
Why?
| | Electronic Health Records | 2 | 2025 | 975 | 0.580 |
Why?
| | Male | 36 | 2025 | 63491 | 0.570 |
Why?
| | Prostate-Specific Antigen | 4 | 2014 | 162 | 0.570 |
Why?
| | Lower Urinary Tract Symptoms | 1 | 2018 | 54 | 0.550 |
Why?
| | Prospective Studies | 11 | 2024 | 7103 | 0.550 |
Why?
| | Recovery of Function | 2 | 2018 | 640 | 0.550 |
Why?
| | Sertoli-Leydig Cell Tumor | 1 | 2016 | 8 | 0.530 |
Why?
| | Bariatric Surgery | 1 | 2020 | 192 | 0.530 |
Why?
| | Acute Kidney Injury | 1 | 2024 | 789 | 0.520 |
Why?
| | Cystoscopy | 1 | 2016 | 18 | 0.520 |
Why?
| | Evidence-Based Medicine | 2 | 2018 | 715 | 0.510 |
Why?
| | Sex Cord-Gonadal Stromal Tumors | 1 | 2015 | 5 | 0.500 |
Why?
| | Child, Preschool | 10 | 2024 | 10507 | 0.500 |
Why?
| | Cause of Death | 2 | 2023 | 392 | 0.500 |
Why?
| | Prostate | 2 | 2012 | 180 | 0.440 |
Why?
| | Patient Care Team | 2 | 2018 | 605 | 0.430 |
Why?
| | Hyperoxaluria, Primary | 2 | 2023 | 14 | 0.410 |
Why?
| | Kidney Calculi | 2 | 2023 | 35 | 0.410 |
Why?
| | Pediatric Obesity | 1 | 2020 | 570 | 0.400 |
Why?
| | Incidence | 4 | 2024 | 2638 | 0.400 |
Why?
| | Tonsillectomy | 2 | 2024 | 79 | 0.400 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2013 | 158 | 0.390 |
Why?
| | Referral and Consultation | 1 | 2017 | 731 | 0.380 |
Why?
| | Retrospective Studies | 13 | 2025 | 14488 | 0.380 |
Why?
| | Adolescent | 12 | 2024 | 20371 | 0.370 |
Why?
| | Azasteroids | 1 | 2011 | 4 | 0.360 |
Why?
| | 5-alpha Reductase Inhibitors | 1 | 2011 | 16 | 0.360 |
Why?
| | Orchiectomy | 3 | 2016 | 67 | 0.350 |
Why?
| | Disease Progression | 4 | 2015 | 2622 | 0.350 |
Why?
| | Kidney Neoplasms | 3 | 2019 | 350 | 0.340 |
Why?
| | Anticarcinogenic Agents | 1 | 2011 | 77 | 0.340 |
Why?
| | Sleep Apnea, Obstructive | 2 | 2024 | 239 | 0.340 |
Why?
| | Registries | 1 | 2018 | 1886 | 0.330 |
Why?
| | Risk Assessment | 4 | 2024 | 3234 | 0.320 |
Why?
| | Neoplasm Staging | 4 | 2016 | 1292 | 0.300 |
Why?
| | Early Detection of Cancer | 2 | 2011 | 369 | 0.300 |
Why?
| | Wilms Tumor | 2 | 2019 | 77 | 0.290 |
Why?
| | Female | 15 | 2025 | 68600 | 0.280 |
Why?
| | Adenoidectomy | 2 | 2024 | 65 | 0.270 |
Why?
| | Sex Factors | 2 | 2025 | 1961 | 0.250 |
Why?
| | Antineoplastic Agents | 3 | 2012 | 2058 | 0.250 |
Why?
| | Case-Control Studies | 3 | 2023 | 3372 | 0.240 |
Why?
| | Fractures, Bone | 1 | 2009 | 392 | 0.220 |
Why?
| | Prognosis | 3 | 2018 | 3791 | 0.220 |
Why?
| | Nephrocalcinosis | 1 | 2023 | 3 | 0.220 |
Why?
| | Nephrolithiasis | 1 | 2023 | 10 | 0.220 |
Why?
| | Young Adult | 6 | 2024 | 12396 | 0.220 |
Why?
| | Neoplasm Metastasis | 2 | 2016 | 610 | 0.210 |
Why?
| | Ureteral Calculi | 1 | 2023 | 13 | 0.210 |
Why?
| | Lithotripsy | 1 | 2023 | 43 | 0.200 |
Why?
| | Analgesia, Epidural | 1 | 2022 | 23 | 0.200 |
Why?
| | Meningomyelocele | 1 | 2023 | 59 | 0.190 |
Why?
| | Survival Analysis | 2 | 2016 | 1271 | 0.190 |
Why?
| | Hydrocephalus | 1 | 2023 | 107 | 0.190 |
Why?
| | Stents | 2 | 2023 | 504 | 0.190 |
Why?
| | Device Removal | 1 | 2022 | 134 | 0.180 |
Why?
| | Cohort Studies | 2 | 2024 | 5408 | 0.180 |
Why?
| | Diphosphonates | 2 | 2011 | 56 | 0.170 |
Why?
| | RANK Ligand | 2 | 2010 | 26 | 0.170 |
Why?
| | Treatment Outcome | 6 | 2023 | 10189 | 0.170 |
Why?
| | Radiotherapy | 2 | 2012 | 187 | 0.170 |
Why?
| | Anastomosis, Surgical | 1 | 2020 | 149 | 0.170 |
Why?
| | Age Factors | 2 | 2018 | 3137 | 0.170 |
Why?
| | Combined Modality Therapy | 2 | 2014 | 1202 | 0.170 |
Why?
| | Caregivers | 2 | 2024 | 813 | 0.160 |
Why?
| | Sex-Determining Region Y Protein | 1 | 2019 | 2 | 0.160 |
Why?
| | WT1 Proteins | 1 | 2019 | 14 | 0.160 |
Why?
| | Emotions | 1 | 2024 | 535 | 0.160 |
Why?
| | Nephrotic Syndrome | 1 | 2019 | 28 | 0.160 |
Why?
| | Disorders of Sex Development | 1 | 2019 | 39 | 0.150 |
Why?
| | Urethral Neoplasms | 1 | 2018 | 1 | 0.150 |
Why?
| | Magnetic Resonance Imaging | 3 | 2019 | 3390 | 0.150 |
Why?
| | Follow-Up Studies | 3 | 2018 | 4886 | 0.150 |
Why?
| | Hypertension, Renal | 1 | 2018 | 16 | 0.150 |
Why?
| | Paraganglioma, Extra-Adrenal | 1 | 2018 | 7 | 0.150 |
Why?
| | Urethral Obstruction | 1 | 2018 | 9 | 0.150 |
Why?
| | Polyps | 1 | 2018 | 11 | 0.150 |
Why?
| | Renal Artery Obstruction | 1 | 2018 | 29 | 0.150 |
Why?
| | Surveys and Questionnaires | 4 | 2024 | 5387 | 0.150 |
Why?
| | Urethra | 1 | 2018 | 52 | 0.140 |
Why?
| | Kidney Failure, Chronic | 1 | 2023 | 547 | 0.140 |
Why?
| | Prenatal Diagnosis | 1 | 2019 | 190 | 0.140 |
Why?
| | Practice Guidelines as Topic | 2 | 2018 | 1493 | 0.140 |
Why?
| | Adult | 8 | 2024 | 35464 | 0.140 |
Why?
| | Pain Management | 1 | 2020 | 321 | 0.140 |
Why?
| | Intestines | 1 | 2020 | 347 | 0.140 |
Why?
| | Decision Making | 1 | 2024 | 849 | 0.140 |
Why?
| | Men's Health | 1 | 2017 | 7 | 0.140 |
Why?
| | Organ Size | 1 | 2018 | 445 | 0.140 |
Why?
| | Infant | 2 | 2024 | 9016 | 0.140 |
Why?
| | Postoperative Period | 1 | 2018 | 327 | 0.130 |
Why?
| | Immunotherapy | 2 | 2011 | 592 | 0.130 |
Why?
| | Review Literature as Topic | 1 | 2017 | 66 | 0.130 |
Why?
| | Tertiary Care Centers | 1 | 2017 | 151 | 0.130 |
Why?
| | Databases, Factual | 2 | 2022 | 1269 | 0.130 |
Why?
| | Feminization | 1 | 2015 | 6 | 0.130 |
Why?
| | Mitotic Index | 1 | 2015 | 26 | 0.130 |
Why?
| | Intermittent Urethral Catheterization | 1 | 2015 | 3 | 0.120 |
Why?
| | Urination Disorders | 1 | 2015 | 13 | 0.120 |
Why?
| | Ultrasonography | 3 | 2019 | 713 | 0.120 |
Why?
| | Colorectal Neoplasms | 1 | 2022 | 751 | 0.120 |
Why?
| | Cloaca | 1 | 2015 | 48 | 0.120 |
Why?
| | Disease-Free Survival | 1 | 2016 | 647 | 0.120 |
Why?
| | Neoplasm Invasiveness | 1 | 2016 | 481 | 0.120 |
Why?
| | Patient Reported Outcome Measures | 1 | 2018 | 370 | 0.110 |
Why?
| | Antibodies, Monoclonal | 2 | 2011 | 1364 | 0.110 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 857 | 0.110 |
Why?
| | Risk Factors | 3 | 2018 | 9747 | 0.110 |
Why?
| | Self Report | 1 | 2018 | 799 | 0.110 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2018 | 742 | 0.110 |
Why?
| | Infant, Newborn | 4 | 2019 | 5753 | 0.110 |
Why?
| | Creatinine | 1 | 2015 | 490 | 0.100 |
Why?
| | Estrogens | 1 | 2015 | 346 | 0.100 |
Why?
| | Quality of Life | 2 | 2018 | 2693 | 0.100 |
Why?
| | Telemedicine | 1 | 2021 | 787 | 0.100 |
Why?
| | Radiation-Protective Agents | 1 | 2012 | 26 | 0.100 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1500 | 0.100 |
Why?
| | Drug Design | 1 | 2013 | 156 | 0.100 |
Why?
| | Alpha Particles | 1 | 2011 | 1 | 0.100 |
Why?
| | Beta Particles | 1 | 2011 | 1 | 0.100 |
Why?
| | Metalloporphyrins | 1 | 2012 | 101 | 0.100 |
Why?
| | Endothelin A Receptor Antagonists | 1 | 2011 | 24 | 0.100 |
Why?
| | Clusterin | 1 | 2011 | 11 | 0.100 |
Why?
| | Blood Chemical Analysis | 1 | 2012 | 95 | 0.100 |
Why?
| | Receptors, Androgen | 1 | 2013 | 147 | 0.100 |
Why?
| | Mitomycin | 1 | 2011 | 32 | 0.090 |
Why?
| | Drug Costs | 1 | 2012 | 100 | 0.090 |
Why?
| | Kidney | 2 | 2019 | 1375 | 0.090 |
Why?
| | Valproic Acid | 1 | 2011 | 47 | 0.090 |
Why?
| | Dutasteride | 1 | 2011 | 4 | 0.090 |
Why?
| | Logistic Models | 1 | 2016 | 1983 | 0.090 |
Why?
| | Bone Density Conservation Agents | 1 | 2011 | 70 | 0.090 |
Why?
| | Carcinoma, Transitional Cell | 1 | 2011 | 60 | 0.090 |
Why?
| | Androstenols | 1 | 2010 | 4 | 0.090 |
Why?
| | Denosumab | 1 | 2010 | 8 | 0.090 |
Why?
| | Tissue Extracts | 1 | 2010 | 19 | 0.090 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2011 | 123 | 0.090 |
Why?
| | Imaging, Three-Dimensional | 2 | 2012 | 530 | 0.090 |
Why?
| | Guideline Adherence | 1 | 2015 | 525 | 0.090 |
Why?
| | Prostatic Hyperplasia | 1 | 2011 | 42 | 0.090 |
Why?
| | Androstenes | 1 | 2010 | 17 | 0.090 |
Why?
| | Dihydrotestosterone | 1 | 2011 | 41 | 0.090 |
Why?
| | Longitudinal Studies | 1 | 2018 | 2713 | 0.090 |
Why?
| | Patient Care Management | 1 | 2011 | 56 | 0.090 |
Why?
| | Biomedical Research | 1 | 2017 | 637 | 0.090 |
Why?
| | Phenylthiohydantoin | 1 | 2010 | 44 | 0.090 |
Why?
| | Taxoids | 1 | 2010 | 98 | 0.090 |
Why?
| | Ultrasound, High-Intensity Focused, Transrectal | 1 | 2010 | 2 | 0.080 |
Why?
| | Antigens, Neoplasm | 1 | 2012 | 309 | 0.080 |
Why?
| | Benzamides | 1 | 2010 | 207 | 0.080 |
Why?
| | Hormone Antagonists | 1 | 2009 | 32 | 0.080 |
Why?
| | Cost-Benefit Analysis | 1 | 2012 | 567 | 0.080 |
Why?
| | Nitriles | 1 | 2010 | 172 | 0.080 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2011 | 209 | 0.080 |
Why?
| | Mobility Limitation | 1 | 2009 | 60 | 0.080 |
Why?
| | Bone Remodeling | 1 | 2009 | 71 | 0.080 |
Why?
| | Collagen Type I | 1 | 2009 | 119 | 0.080 |
Why?
| | Risk | 1 | 2011 | 854 | 0.080 |
Why?
| | Antioxidants | 1 | 2012 | 557 | 0.080 |
Why?
| | Middle Aged | 6 | 2016 | 31075 | 0.080 |
Why?
| | Aged | 4 | 2016 | 22030 | 0.080 |
Why?
| | Continuity of Patient Care | 1 | 2011 | 275 | 0.080 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2013 | 755 | 0.070 |
Why?
| | Mutation | 1 | 2019 | 3715 | 0.070 |
Why?
| | Biomarkers, Tumor | 1 | 2014 | 1181 | 0.070 |
Why?
| | Computer Simulation | 1 | 2011 | 941 | 0.070 |
Why?
| | Software | 1 | 2011 | 607 | 0.060 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2011 | 1360 | 0.060 |
Why?
| | Protein Kinase Inhibitors | 1 | 2011 | 889 | 0.060 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2010 | 758 | 0.060 |
Why?
| | Peptides | 1 | 2009 | 924 | 0.060 |
Why?
| | Mass Screening | 1 | 2011 | 1147 | 0.060 |
Why?
| | Calcium Oxalate | 1 | 2023 | 5 | 0.050 |
Why?
| | Ambulatory Surgical Procedures | 1 | 2024 | 55 | 0.050 |
Why?
| | Polysomnography | 1 | 2024 | 161 | 0.050 |
Why?
| | Ureteroscopy | 1 | 2023 | 16 | 0.050 |
Why?
| | Predictive Value of Tests | 2 | 2022 | 1944 | 0.050 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2011 | 1565 | 0.050 |
Why?
| | Ventriculoperitoneal Shunt | 1 | 2023 | 38 | 0.050 |
Why?
| | Colostomy | 1 | 2022 | 26 | 0.050 |
Why?
| | Animals | 3 | 2013 | 35219 | 0.050 |
Why?
| | Morphine | 1 | 2022 | 133 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2022 | 286 | 0.050 |
Why?
| | Internship and Residency | 1 | 2011 | 1049 | 0.050 |
Why?
| | Urologists | 1 | 2021 | 17 | 0.040 |
Why?
| | United States | 1 | 2017 | 13873 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2023 | 864 | 0.040 |
Why?
| | Signal Transduction | 1 | 2013 | 4913 | 0.040 |
Why?
| | Cytoskeletal Proteins | 1 | 2019 | 146 | 0.040 |
Why?
| | Oxygen | 1 | 2023 | 911 | 0.040 |
Why?
| | Patient Readmission | 1 | 2024 | 664 | 0.040 |
Why?
| | Pilot Projects | 1 | 2023 | 1584 | 0.040 |
Why?
| | Normetanephrine | 1 | 2018 | 2 | 0.040 |
Why?
| | Metanephrine | 1 | 2018 | 2 | 0.040 |
Why?
| | Cystography | 1 | 2018 | 1 | 0.040 |
Why?
| | Renin | 1 | 2018 | 31 | 0.040 |
Why?
| | Lymph Node Excision | 1 | 2019 | 164 | 0.040 |
Why?
| | Urinary Retention | 1 | 2018 | 20 | 0.040 |
Why?
| | Nephrectomy | 1 | 2019 | 160 | 0.040 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2019 | 381 | 0.040 |
Why?
| | DNA Mutational Analysis | 1 | 2019 | 387 | 0.040 |
Why?
| | Abnormalities, Multiple | 1 | 2019 | 178 | 0.030 |
Why?
| | Norepinephrine | 1 | 2018 | 210 | 0.030 |
Why?
| | Patient Satisfaction | 1 | 2021 | 628 | 0.030 |
Why?
| | Epithelium | 1 | 2018 | 311 | 0.030 |
Why?
| | Computed Tomography Angiography | 1 | 2018 | 115 | 0.030 |
Why?
| | Global Burden of Disease | 1 | 2017 | 18 | 0.030 |
Why?
| | Urologic Neoplasms | 1 | 2017 | 25 | 0.030 |
Why?
| | Infertility, Male | 1 | 2017 | 60 | 0.030 |
Why?
| | Quality-Adjusted Life Years | 1 | 2017 | 106 | 0.030 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2019 | 398 | 0.030 |
Why?
| | Genetic Testing | 1 | 2019 | 428 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2017 | 421 | 0.030 |
Why?
| | Endoscopy | 1 | 2018 | 270 | 0.030 |
Why?
| | Urinary Diversion | 1 | 2015 | 12 | 0.030 |
Why?
| | Kidney Function Tests | 1 | 2015 | 152 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2019 | 1424 | 0.030 |
Why?
| | Pandemics | 1 | 2021 | 1477 | 0.030 |
Why?
| | Image-Guided Biopsy | 1 | 2012 | 37 | 0.030 |
Why?
| | Penis | 1 | 2012 | 35 | 0.020 |
Why?
| | Erectile Dysfunction | 1 | 2012 | 39 | 0.020 |
Why?
| | Radiation, Ionizing | 1 | 2012 | 76 | 0.020 |
Why?
| | Prostatectomy | 1 | 2012 | 106 | 0.020 |
Why?
| | Testis | 1 | 2012 | 144 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2023 | 1899 | 0.020 |
Why?
| | Neoplasm Grading | 1 | 2012 | 285 | 0.020 |
Why?
| | Glomerular Filtration Rate | 1 | 2015 | 707 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2022 | 5057 | 0.020 |
Why?
| | Biopsy, Needle | 1 | 2011 | 189 | 0.020 |
Why?
| | Drug Synergism | 1 | 2011 | 369 | 0.020 |
Why?
| | Efficiency | 1 | 2011 | 91 | 0.020 |
Why?
| | DNA Damage | 1 | 2012 | 384 | 0.020 |
Why?
| | Tumor Cells, Cultured | 1 | 2011 | 939 | 0.020 |
Why?
| | Reference Values | 1 | 2011 | 793 | 0.020 |
Why?
| | Workload | 1 | 2011 | 152 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2019 | 2525 | 0.020 |
Why?
| | Safety | 1 | 2011 | 330 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2011 | 1037 | 0.020 |
Why?
| | Skin | 1 | 2012 | 721 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2012 | 2387 | 0.020 |
Why?
| | Pregnancy | 1 | 2019 | 6384 | 0.020 |
Why?
| | Time Factors | 1 | 2017 | 6549 | 0.020 |
Why?
| | Models, Biological | 1 | 2012 | 1718 | 0.010 |
Why?
| | Rats | 1 | 2012 | 5462 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2011 | 3067 | 0.010 |
Why?
|
|
Rove's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|